In addition, treatment with MM-102, the inhibitor of mixed-lineage leukemia 1(MLL1) or myeloid/lymphoid, H3K4 methyltransferase, has been found to effectively prevent fibrosis in mice undergoing a transition from AKI to CKD after ischemia-reperfusion injury [223]. Here, KMT2A is linked to chronic kidney disease.